Edwards Lifesciences (EW) Q1 2026: TMTT Grows 42%, Multi-Therapy Portfolio Drives Guidance Raise

2026-04-23 | By EarningsIQ Research

Edwards Lifesciences delivered broad-based growth in Q1 2026, led by a 42% surge in TMTT sales and robust TAVR momentum, prompting management to raise full-year guidance across major business lines. Strategic investments in clinical evidence, next-gen technology, and indication expansion are reinforcing Edwards’ competitive moat in structural heart therapies. With a diversified product engine and disciplined capital allocation, the company is positioning for sustained double-digit growth and margin expansion into 2027 and beyond.

Summary

• TMTT Portfolio Expansion: Strong adoption of differentiated mitral and tricuspid therapies is accelerating category creation and patient reach.
• TAVR Data Leadership: Long-term evidence and proactive disease management are driving renewed clinical focus and market growth.
• Strategic Capital Deployment: Innovation investments and disciplined buybacks support multi-year growth and operating leverage.

Performance Analysis

Edwards Lifesciences posted a robust Q1 2026 with double-digit sales growth across all product groups, reflecting the company’s execution on its structural heart disease strategy. TAVR, transcatheter aortic valve replacement, delivered global sales growth, benefiting from increased clinical focus on early intervention and the impact of long-term durability data for the SAPIEN platform. Notably, performance outside the US outpaced domestic results, aided by a competitor’s exit in Europe and stable pricing worldwide.

TMTT, transcatheter mitral and tricuspid therapies, was the standout, with a 42% year-over-year sales increase, fueled by double-digit procedural growth in both mitral and tricuspid segments. New product launches like Sapien M3 and expanding adoption of Pascal and Evoque are broadening the patient base and deepening physician engagement. Surgical therapies maintained mid-single-digit growth, propelled by the global uptake of resilient tissue technologies such as Inspiris and Connect.

• Margin Structure Resiliency: Gross margin remained in line with guidance despite FX drag and manufacturing investments, while operating margin benefited from top-line outperformance and phased spending.
• Expense Prioritization: R&D spend was up in dollar terms but down as a percentage of sales, reflecting disciplined prioritization and leverage from revenue growth.
• Capital Allocation Discipline: Edwards executed $520 million in share repurchases, maintaining a strong balance sheet and lowering share count for 2026.

Management’s guidance raise for both revenue and EPS reflects confidence in the durability of current trends and the impact of innovation-driven growth levers across the portfolio.

Executive Commentary

Strategic Positioning

1. Evidence-Based Differentiation in TAVR

Edwards’ SAPIEN platform is reinforced by 7- and 10-year clinical data, establishing benchmark durability and supporting a shift toward earlier intervention in severe aortic stenosis. The company’s ability to generate and communicate world-class evidence is deepening physician trust and expanding the addressable patient pool, with momentum visible in both US and international procedural growth. Regulatory tailwinds, such as the ongoing CMS NCD review, could further enhance access and accelerate category growth.

2. Broadening TMTT Portfolio and Category Creation

The TMTT franchise is evolving into a comprehensive suite of repair and replacement options, allowing for personalized therapy selection across diverse patient profiles. Strong adoption of Pascal, Evoque, and the newly launched Sapien M3 is driving double-digit procedural growth and market share gains, with upcoming next-gen launches expected to further catalyze the franchise. Management’s $2 billion TMTT revenue target for 2030 underlines the conviction in this platform’s long-term potential.

3. Surgical Platform and Pipeline Progression

Surgical therapies remain a stable growth engine, with resilient tissue technologies like Inspiris and Connect gaining traction globally. Launches such as Mitris and the upcoming Triformis tricuspid valve, along with the left atrial appendage closure program, are expanding the surgical portfolio’s reach and supporting multi-segment growth.

4. Investment in Innovation and Operating Leverage

Edwards is channeling capital into clinical evidence generation, technology advancement, and indication expansion, while maintaining disciplined R&D prioritization. The company anticipates annual operating margin expansion of 50 to 100 basis points beyond 2027, leveraging top-line growth and operational scale.

5. Capital Allocation and Shareholder Returns

With $2.4 billion in cash and a $1.5 billion buyback authorization remaining, Edwards is balancing innovation investment with capital returns. The Q1 accelerated share repurchase demonstrates confidence in the long-term value creation outlook.

Key Considerations

Edwards’ Q1 2026 results highlight a company executing across multiple dimensions of innovation, commercialization, and capital deployment. The following factors are most critical for investors tracking the company’s evolving trajectory:

• Clinical Evidence as a Growth Catalyst: Ongoing presentation of long-term TAVR and TMTT data is shaping referral patterns and expanding indications, supporting durable category leadership.
• Portfolio Depth and Personalization: The breadth of repair and replacement options in both TAVR and TMTT positions Edwards to address diverse and underpenetrated patient populations.
• Global Execution and Market Expansion: International growth, especially in Europe and Japan, is outpacing the US and benefiting from competitor exits and evolving guidelines.
• Expense and Margin Management: R&D and SG&A are being tightly managed relative to sales, preserving margin expansion opportunities even as innovation investment continues.
• Regulatory and Policy Tailwinds: CMS NCD review and new breakthrough therapy policies could accelerate access and reinforce Edwards’ first-mover advantage.

Risks

Key risks include regulatory uncertainty, particularly regarding CMS coverage decisions and potential delays or changes in reimbursement for new therapies. Competitive dynamics remain fluid, with new entrants and evolving technology in both TAVR and TMTT. Foreign exchange volatility and manufacturing cost pressures could impact margins, while execution risk exists around the scaling of recently launched and pipeline products.

Forward Outlook

For Q2 2026, Edwards guided to:

• Revenue of $1.66 to $1.74 billion
• Adjusted EPS of $0.70 to $0.76

For full-year 2026, management raised guidance:

• Company-wide sales growth of 9% to 11%
• TAVR sales growth of 7% to 9%
• TMTT sales of $740 to $780 million (35% to 45% growth)
• Adjusted EPS of $2.95 to $3.05

Management noted that top-line outperformance, robust pipeline momentum, and disciplined expense management underpin the new guidance, while cautioning that tougher second-half comps and variable catalyst timing could create intra-year variability.

Takeaways

Edwards Lifesciences is demonstrating strong execution on its strategy to lead in structural heart therapies, with TMTT and TAVR both delivering above-market growth and expanding their clinical and commercial moats.

• Category Leadership Through Evidence: Durable outcomes data and proactive disease management are driving both market growth and share gains, especially as competitor platforms face scrutiny.
• Multi-Platform Innovation Engine: The company’s broadening portfolio in TMTT and surgical solutions is enabling personalized therapy and deeper market penetration.
• Forward Watchpoint: Investors should monitor upcoming clinical trial readouts, regulatory decisions, and the scaling of new product launches for signals on sustained growth and competitive positioning.

Conclusion

Edwards Lifesciences enters the remainder of 2026 with strong momentum, a reinforced innovation pipeline, and a disciplined approach to capital allocation. Sustained double-digit growth and margin expansion appear achievable, provided the company continues to execute on clinical, commercial, and operational fronts.

Industry Read-Through

Edwards’ results underscore the centrality of clinical evidence and portfolio depth in structural heart innovation. Competitors in transcatheter valve and repair markets face increasing pressure to match long-term data and procedural versatility, while the shift toward earlier intervention and personalized therapy is likely to accelerate across cardiovascular device categories. Policy momentum for breakthrough therapies and evolving reimbursement frameworks could benefit other medtech innovators with robust evidence-generation strategies, while those lacking differentiated data may see referral and access headwinds intensify.

EW Healthcare Medical Devices Structural Heart Innovation TAVR TMTT Clinical Evidence